First-in-Human Therapeutic Targeting of MYCN driven Pediatric and Adult Cancers by the 3'UTRMYCN M1-14+IO-Nanocage

计划入组 56 人 · 首次发布于 2026 年 7 月 20 日

Kiinteistö oy Espoon Pellavaniementie 14

Finland

Swedish University of Agricultural Sciences

Sweden

黑龙江省知润药业有限公司

FDA Grants Orphan Drug and Rare Pediatric Disease Designations to UTR Therapeutics' MYCN-Targeting RNA Therapeutic

First In Vivo PET Evidence Reveals Widespread M1 Receptor Deficits in Living Schizophrenia Patients

NCCN Updates Prostate Cancer Guidelines: Stratified Treatment for Metastatic Hormone-Sensitive Disease